ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
63,344.06
-0.62%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Immuneering Corporation (IMRX) Quote

Immuneering Corporation

Immuneering Corporation (IMRX)

NASDAQ
1.47
0.04
(2.80%)
Closed April 26 4:00PM
Delayed by 15 minutes
1.47
0.00
(0.00%)
After Hours: 5:12PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.47
Bid
1.45
Ask
1.48
Volume
295,784
1.43 Day's Range 1.51
1.40 52 Week Range 11.92
Market Cap
42.754M
Previous Close
1.43
Open
1.43
Last Trade
1
@
1.45
Last Trade Time
Financial Volume
$ 434,020
VWAP
1.4674
Average Volume (3m)
758,322
Shares Outstanding
29,283,272
Dividend Yield
-
PE Ratio
-0.80
Earnings Per Share (EPS)
-1.83
Revenue
-
Net Profit
-53.47M

About Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary comput... Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.immuneering.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Immuneering Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMRX. The last closing price for Immuneering was $1.43. Over the last year, Immuneering shares have traded in a share price range of $ 1.40 to $ 11.92.

Immuneering currently has 29,283,272 shares outstanding. The market capitalization of Immuneering is $42.75 million. Immuneering has a price to earnings ratio (PE ratio) of -0.80.

IMRX Latest News

More News

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth...

April 09 2024
GlobeNewswire Inc.

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines...

April 03 2024
GlobeNewswire Inc.

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1...

March 27 2024
GlobeNewswire Inc.

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled...

March 14 2024
GlobeNewswire Inc.

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines...

March 12 2024
GlobeNewswire Inc.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...

March 11 2024
GlobeNewswire Inc.

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines...

March 05 2024
GlobeNewswire Inc.

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines...

March 04 2024
GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 01 2024
Edgar (US Regulatory)

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104...

March 01 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.32-17.87709497211.791.821.44061121.62007184CS
4-1.36-48.05653710252.833.151.45748732.09537888CS
12-4.15-73.84341637015.627.681.47583222.61898486CS
26-4.03-73.27272727275.58.891.43869572.97801805CS
52-8.83-85.728155339810.311.921.42338994.10375211CS
156-18.03-92.461538461519.533.991.41428177.51437746CS
260-18.03-92.461538461519.533.991.41428177.51437746CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

IMRX Discussion

View Posts
axelvento axelvento 5 days ago
Peter Feinberg, recently bought US$183k worth of stock, paying US$2.44 for each share
👍️0
herbied47 herbied47 1 week ago
A lot to like except the share price sadly.
👍️0
axelvento axelvento 2 weeks ago
Results:IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models.
IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.
In a human pancreatic cancer cell line (MIA PaCa-2) tumor xenograft model, IMM-1-104 alone showed greater tumor growth inhibition (TGI) and better durability than any single or combination chemotherapy tested.
At day 39, antitumor activity (TGI%) was 103% for IMM-1-104 at 125 mg/kg BID PO, 25.2% for GEM at 60 mg/kg IP Q4D, 62.2% for PAC at 10 mg/kg IV Q4D, and 36.6% for 5FU at 50 mg/kg IP Q4D.
In the Phase 2a portion of Immuneering’s ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in select combinations with approved chemotherapeutic agents. The Phase 2a portion includes five arms, three of which focus on patients with pancreatic cancer. Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting. The company expects initial data from multiple Phase 2a arms in 2024.
https://ir.immuneering.com/news-releases/news-release-details/imm-1-104-synergistic-chemotherapy-pancreatic-cancer-models
👍️0
axelvento axelvento 3 weeks ago
The top 5 shareholders own 54% of the company

the third-largest shareholder, also happens to hold the title of Member of the Board of Directors
👍️0
axelvento axelvento 3 weeks ago
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Company expects multiple readouts from its Phase 1/2a clinical trial in 2024
👍️0
axelvento axelvento 3 weeks ago
Peter Feinberg, recently bought US$183k worth of stock, paying US$2.44 for each share.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imrx/immuneering/news/insider-spends-us183k-buying-more-shares-in-immuneering
👍️0
herbied47 herbied47 3 weeks ago
It’s easy to find in the filings. Not that is has helped the share price any.
👍️0
dealerschool2006 dealerschool2006 3 weeks ago
how do you know insider buying has occurred for IMRX???
👍️0
herbied47 herbied47 1 month ago
Good to see that insider buying! Give it a week or two and I wouldn‘t be surprised to see it trading back between $5 to $6. Certainly no need to be a seller now. Have a great day all and God bless!
👍️0
glenn1919 glenn1919 1 month ago
IMRX................................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783
👍️0
herbied47 herbied47 1 month ago
Should be back over $5 soon.
👍️0
axelvento axelvento 1 month ago
management started dosing patients in the phase IIa portion of the study. This portion will evaluate a 320mg dose of IMM-1-104 as monotherapy in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and melanoma, and as combination therapy in PDAC.

Initial data from the phase IIa portion is expected later this year
👍️0
Monksdream Monksdream 1 month ago
IMRX under $2
👍️0
Monksdream Monksdream 1 month ago
IMRX new 52. Lo
👍️0
willlbone willlbone 1 month ago
Maybe insiders got some news, like dilution is coming to pay for Phase 2.
👍️0
dealerschool2006 dealerschool2006 1 month ago
IMRX fell today after positive results...
👍️0

Your Recent History

NASDAQ
IMRX
Immuneering
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved